Physician profile
Leon Rafailov
NPI 1396156121
$4,801.73
in general payments reported to CMS, 2019-2025
17 companies · $567 in 2025
The $567 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $210 · 2021: $2,646 · 2022: $777 · 2023: $399 · 2024: $203 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,006.13 | 2020-2023 | Tepezza |
| Amgen INC. | $306.82 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $244.90 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $232.55 | 2021-2022 | |
| Genentech USA, INC. | $168.93 | 2021 | |
| Bausch & Lomb Americas INC. | $165.08 | 2022-2025 | Xipere, Vyzulta |
| Kala Pharmaceuticals, INC. | $136.28 | 2021 | |
| Genzyme Corporation | $131.40 | 2022 | |
| Ani Pharmaceuticals, INC. | $125.30 | 2024-2025 | Purified Cortrophin Gel |
| Biotissue Holdings INC. | $105.73 | 2022-2023 | |
| Allergan, INC. | $50.16 | 2021 | |
| Dompe US, INC. | $31.38 | 2025 | Oxervate |
| Sight Sciences, INC. | $25.86 | 2022 | |
| Harrow Eye, LLC | $21.43 | 2024 | Vevye |
| Coopervision INC. | $17.35 | 2023 | Misight Contact Lens |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $16.92 | 2022 | |
| Eyevance Pharmaceuticals LLC | $15.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Rafailov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.